A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
PLUS THERAPEUTICS, INC.
PSTV
$296M
Mkt Cap
$3.83
+1.32%
PLUS THERAPEUTICS, INC. (PSTV) has a 5-year average return on invested capital (ROIC) of -98.9%. This is below average and may indicate limited pricing power.
PLUS THERAPEUTICS, INC. (PSTV) has a market capitalization of $296M. It is classified as a small-cap stock.
PLUS THERAPEUTICS, INC. (PSTV) does not currently pay a regular dividend.
PLUS THERAPEUTICS, INC. (PSTV) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
PLUS THERAPEUTICS, INC. (PSTV) generated $-21 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PLUS THERAPEUTICS, INC. (PSTV) has a debt-to-equity ratio of 0.94. This indicates moderate leverage.
PLUS THERAPEUTICS, INC. (PSTV) reported earnings per share (EPS) of $-0.29 in its most recent fiscal year.
References to “Plus Therapeutics,” the “Company,” “we,” “us” and “our” refer to Plus Therapeutics, Inc. References to “Notes” refer to the Notes to Financial Statements included herein (refer to Item 8). Plus Therapeutics is a U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (“CNS”) cancers. Our novel radioactive drug formulations and medical devices and therapeutic candidates are designed to deliver safe and effective doses of radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as rhenium isotopes with nanoliposomes and microspheres.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -22M | -22M | -13M | -13M | -20M | -8.2M |
| EPS | $-0.29 | $-0.29 | $-0.13 | $-0.24 | $-11.58 | $-27.90 |
| Free Cash Flow | -21M | -21M | -11M | -13M | -13M | -8.5M |
| ROIC | -343.9% | -74.0% | -175.0% | -92.4% | -65.2% | -88.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.94 | 0.94 | -0.45 | -4.29 | 1.09 | 6.27 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -15M | -15M | -15M | -13M | -20M | -9.6M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -560.2% | -560.2% | 252.1% | - | -314.6% | -271.9% |
| Shares Outstanding | 77M | 77M | 100M | 57M | 4M | 1M |
| Metric | 2019 | 2020 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | 3.7M | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | 35.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 17M | 15M | 19M | 16M | 12M | 5.5M | 5.4M | 2.7M | 9.7M | 9.7M | 11M | 8.4M | 8.4M |
| SG&A | 16M | 16M | 9.8M | 8.6M | 7.6M | 5.6M | 5.3M | 6.4M | 10M | 8.5M | 9.9M | 12M | 12M |
| EBIT | -31M | -32M | -15M | -20M | -21M | -8.8M | -3.7M | -9.6M | -20M | -13M | -15M | -15M | -15M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | -238.7% | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -26M | -39M | -19M | -22M | -27M | N/A | -11M | -8.2M | -20M | -13M | -13M | -22M | -22M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -163.5% | N/A | 0.0% | N/A | N/A | 0.0% | 0.0% |
| Non-Recurring | -257K | 42K | 3K | 0 | 0 | 0 | -6.5M | 0 | 0 | -2K | 0 | 16K | 16K |
| Returns on Capital | |||||||||||||
| ROIC | -114.8% | -199.8% | -94.1% | -86.7% | -109.7% | N/A | -21.5% | -88.0% | -65.2% | -92.4% | -175.0% | -74.0% | N/M |
| ROE | -835.8% | N/A | -159.0% | -190.1% | -222.3% | N/A | -358.4% | -271.9% | -314.6% | N/A | 252.1% | -560.2% | -560.2% |
| ROA | -61.4% | -95.4% | -50.8% | -61.0% | -80.5% | N/A | -48.5% | -68.1% | -84.9% | -75.5% | -144.0% | -195.0% | -137.1% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -35M | -30M | -20M | -20M | -18M | -12M | -5.9M | -8.4M | -13M | -13M | -11M | -21M | -21M |
| Free Cash Flow | -35M | -31M | -21M | -20M | -18M | -12M | -6.0M | -8.5M | -13M | -13M | -11M | -21M | -21M |
| Owner Earnings | -40M | -34M | -24M | -22M | -21M | -14M | -6.9M | -9.0M | -14M | -14M | -12M | -23M | -23M |
| CapEx | 519K | 764K | 611K | 67K | 295K | 133K | 67K | 93K | 509K | 160K | 146K | 67K | 67K |
| Maint. CapEx | 1.6M | 779K | 1.1M | 1.2M | 2.2M | 2.0M | 896K | 366K | 619K | 628K | 872K | 445K | 445K |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 1.6M | 779K | 1.1M | 1.2M | 2.2M | 2.0M | 896K | 366K | 619K | 628K | 872K | 445K | 445K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 75K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 126K | 374K | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.4% | 5.8% | 0.0% | 0.0% |
| Stock-Based Comp | 3.6M | 3.1M | 2.0M | 1.1M | 753K | 355K | 127K | 247K | 606K | 569K | 550K | 1.5M | 1.5M |
| Debt Repayment | 22M | 2.0M | 25M | 0 | 4.7M | 0 | 3.7M | 5.3M | 1.6M | 1.6M | 4.0M | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | 6.1M | 2.6M | -12M | 5.0M | 4.1M | 8.9M | 4.6M | 2.3M | -29M | -2.8M | 465K | -4.8M | -482K |
| Cash & Equiv. | 16M | 15M | 14M | 13M | 9.5M | 5.3M | 18M | 8.3M | 18M | 8.6M | 76K | 4.3M | 4.3M |
| Long-Term Debt | 23M | 18M | 17M | 11M | 14M | 14M | 11M | 6.3M | 3.8M | 1.6M | 4.0M | 3.7M | 3.7M |
| Debt/Equity | 8.39 | -4.46 | 1.37 | 1.61 | 1.05 | 2.72 | 19.07 | 6.27 | 1.09 | -4.29 | -0.45 | 0.94 | 0.94 |
| Interest Coverage | -9.0 | -7.4 | -4.5 | -7.6 | -10.1 | -4.6 | -2.0 | -8.7 | -27.7 | -33.7 | -82.1 | -27.9 | -27.9 |
| Equity | 3.1M | -5.7M | 12M | 11M | 13M | 5.2M | 1.2M | 3.0M | 6.4M | -1.3M | -8.9M | 4.0M | 4.0M |
| Total Assets | 42M | 39M | 38M | 35M | 32M | 24M | 23M | 12M | 24M | 11M | 6.6M | 16M | 16M |
| Total Liabilities | 39M | 44M | 25M | 24M | 19M | 19M | 22M | 9.1M | 17M | 13M | 16M | 12M | 12M |
| Intangibles | 9.3M | 9.4M | 9.0M | 8.4M | 7.2M | 6.0M | 372K | 458K | 466K | 42K | 469K | 333K | 333K |
| Retained Earnings | -301M | -338M | -357M | -379M | -402M | -414M | -425M | -434M | -467M | -481M | -493M | -516M | -516M |
| Working Capital | 9.7M | 5.8M | 13M | 6.2M | -3.6M | -7.9M | 5.3M | 636K | 10.0M | -893K | -10M | 2.9M | 2.9M |
| Current Assets | 25M | 22M | 21M | 19M | 15M | 9.6M | 20M | 9.2M | 22M | 9.8M | 5.3M | 15M | 15M |
| Current Liabilities | 15M | 16M | 8.4M | 13M | 18M | 18M | 14M | 8.5M | 12M | 11M | 16M | 12M | 12M |
| Per Share Data | |||||||||||||
| EPS | -25.88 | -31.85 | -137.35 | -5.66 | -36.41 | -192.38 | -124.05 | -27.90 | -11.58 | -0.24 | -0.13 | -0.29 | -0.29 |
| Owner EPS | -39.35 | -28.27 | -167.06 | -5.60 | -28.72 | -106.89 | -26.78 | -6.12 | -3.32 | -0.25 | -0.12 | -0.29 | -0.29 |
| Book Value | 3.10 | -4.71 | 86.40 | 2.82 | 17.75 | 38.96 | 4.48 | 2.05 | 1.51 | -0.02 | -0.09 | 0.05 | 0.05 |
| Cash Flow/Share | -34.17 | -25.07 | -144.88 | -5.02 | -24.75 | -89.30 | -22.83 | -5.71 | -3.03 | -0.23 | -0.11 | -0.27 | -0.28 |
| Dividends/Share | 0.00 | 0.00 | 0.53 | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.0M | 1.2M | 0.1M | 3.9M | 0.7M | 0.1M | 0.3M | 1.5M | 4.3M | 56.5M | 99.8M | 77.2M | 77.2M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -13.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 57.0 | N/A | 2.3 | 7.4 | 3.1 | 11.1 | 44.8 | 17.1 | N/A | N/A | N/A | N/A | 74.0 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 115.2 | 30.3 | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -19.6% | -77.5% | -75.0% | -24.1% | -45.1% | -20.8% | -11.5% | -16.4% | N/A | -45.0% | -166.3% | N/A | -7.0% |
| Market Cap | 179M | 40M | 28M | 81M | 41M | 58M | 52M | 52M | 0 | 29M | 6.4M | 0 | 296M |
| Avg. Price | 284,250.00 | 208,537.35 | 65,986.61 | 18,139.92 | 6,843.68 | 1,328.39 | 150.61 | 32.69 | 0.00 | 3.23 | 1.69 | 0.00 | 3.83 |
| Year-End Price | 299,250.00 | 56,250.00 | 22,500.00 | 10,200.00 | 1,875.00 | 225.00 | 36.90 | 35.10 | 0.00 | 1.70 | 1.16 | 0.00 | 3.83 |
PLUS THERAPEUTICS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
PLUS THERAPEUTICS, INC. (PSTV) has a return on equity (ROE) of -560.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 17 years of financial data for PLUS THERAPEUTICS, INC. (PSTV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PLUS THERAPEUTICS, INC. (PSTV) has a book value per share of $0.05, based on its most recent annual SEC filing.